Pyridine compounds which are useful as anti-arrhythmic agents
申请人:Pfizer Inc.
公开号:US04968704A1
公开(公告)日:1990-11-06
A series of novel aryloxyalkylamino- and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or by a ureido or acylamino group located at the para-position of the ring with respect to the aforesaid alkylamino side chain. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Methods for preparing all these compounds from known starting materials are provided.
Amino-pyridine compounds useful as anti-arrhythmic agents
申请人:Pfizer Inc.
公开号:US05057528A1
公开(公告)日:1991-10-15
A series of novel aryloxyalkylamino - and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salt, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or by a ureido or acylamino group located at the para-position of the ring with respect to the aforesaid alkylamino side chain. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Methods for preparing all these compounds from know starting materials are provided.
The invention provides antiarrhythmic agents of the formula:
and
and pharmaceutically acceptable salts thereof,
wherein X is 0 or N-(C₁-C₄ alkyl);
R is C₁-C₄ alkyl;
R¹ is R²SO₂NH- or R²CONH-,
wherein R² is C₁-C₄ alkyl, C₃-C₇ cycloalkyl or R³R⁴N-,
wherein R³ und R⁴ are each independently selected from H and C₁-C₄ alkyl;
"Het" is either (a) 2-, 3- or 4-pyridyl optionally substituted by 1 or 2 substituents, each independently selected from -NH₂ and C₁-C₄ alkyl, or (b) 2-imidazolyl optionally substituted by 1 or 2 C₁-C₄ alkyl groups;
m is 0, 1 or 2;
n is 2, 3 or 4;
and p is 1 or 2.
A compound of Formula 1:
(wherein A is optionally substituted lower alkylene (substituent: mono- or di-lower alkyl, lower alkylidene, or lower alkylene having two or more carbons); Z
+
is either of the groups shown below:
(wherein R
1
and R
2
are each independently hydrogen, optionally substituted amino lower alkyl, optionally substituted aminocycloalkyl, optionally substituted cyclic amino, or optionally substituted cyclic amino lower alkyl; R
9
is hydrogen or lower alkyl, or R
1
and R
9
taken together with an adjacent N atom may form optionally substituted cyclic amino; R
3
is hydrogen or amino; X is N or CR
4
(R
4
is hydrogen or optionally substituted lower alkyl)), a pharmaceutically acceptable salt or a solvate thereof.